Bioxodes granted European patent for thromboinflammation lead asset

May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company specializing in the development of therapies for thrombotic and inflammatory diseases, has announced that the European Patent Office intends to grant a patent for their leading therapy, BIOX-101 (Ir-CPI). This patent will further enhance the protection of BIOX-101 in the area of thromboinflammation, adding to Bioxodes' robust portfolio of intellectual property, which already includes an approval in Australia from June 2022 and a pending patent from Russia’s Center for Intellectual Property Rights.

According to Marc Dechamps, the Chief Executive Officer of Bioxodes, this decision by the European Patent Office is crucial for the progress of BIOX-101, a pioneering drug aimed at providing new hope for patients suffering from hemorrhagic stroke and potentially other related conditions. He emphasized that the European Patent Office’s decision could positively influence patent outcomes in other jurisdictions as well.

BIOX-101 has had patent protection in the US and Europe for several years, particularly for its active component and its usage in treating thrombosis. The active ingredient in BIOX-101 is derived from a protein found in tick saliva, which effectively prevents blood clot formation without raising the risk of bleeding. Additionally, by inhibiting the activation of neutrophils, BIOX-101 helps prevent acute neuroinflammatory events linked with intracerebral hemorrhage. The drug is being developed for treating patients within the first 72 hours of a hemorrhagic stroke and is currently undergoing Phase 2a clinical trials in a randomized open-label proof-of-concept study involving 32 patients in Belgium.

Bioxodes, founded in 2013, is a clinical stage biopharmaceutical company based in Gosselies, Belgium. The company focuses on novel therapies for preventing and treating thrombotic and inflammatory diseases. Their main asset, BIOX-101, is a first-in-class drug candidate targeted at patients with thromboinflammatory diseases. The unique mechanism of action of BIOX-101 forms the basis for an innovative pipeline of drug candidates aimed at preventing (thrombo)inflammatory diseases. Bioxodes has secured €34 million in funding from Belgian investment funds and business angels, including €12 million in non-dilutive funding from the Wallonia region. Globally, Bioxodes holds granted and pending patents related to Ir-CPI.

Ultimately, the advancements and patent protections for BIOX-101 not only bolster Bioxodes' intellectual property portfolio but also pave the way for significant medical breakthroughs in the treatment of thromboinflammatory conditions. As the company continues to advance its clinical trials and secure patent rights worldwide, it stands poised to make a substantial impact in the field of biopharmaceuticals.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!